Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-23T07:55:31.306Z Has data issue: false hasContentIssue false

Pharmacologic Treatments for Anxiety

Published online by Cambridge University Press:  07 November 2014

Extract

While the public health perspective prioritizes large populations of affected individuals, our job as clinicians is to help one patient at a time. Over the last 10–20 years, there has been marked improvement in pharmacologic and psychosocial interventions available for patients with anxiety disorders (Slide 8).

The use of antidepressants, particularly the serotonergic and serotonergic noradrenergic agents, have received increased attention as first-line treatment for most of the anxiety disorders, including panic disorder, social phobia, posttraumatic stress disorder (PTSD), and generalized anxiety disorder (GAD). Antidepressants are often used as first-line therapy for anxiety disorders because of their broad spectrum of efficacy against common comorbidities, especially depression, and because of concern about benzodiazepine-associated dependence, abuse liability, and lack of efficacy for depression and other comorbidities (Slide 9).

These newer antidepressants have advantages over the older antidepressants, particularly the tricyclics and the monoamine oxidase inhibitors, in that they are generally better tolerated and more appropriate for use in potentially suicidal patients because they are less lethal in overdose. However, there are some side effects that may limit their use in some patients. In the case of the serotonergic antidepressants, many patients are hesitant to initiate or maintain treatment due to concerns about sexual dysfunction.

Type
Monograph Supplement
Copyright
Copyright © Cambridge University Press 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Pollack, MH, Simon, NM, Worthington, JJ, et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol. 2003;17(3):276282.CrossRefGoogle ScholarPubMed
2. Goddard, AW, Brouette, T, Almai, A, et al. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry. 2001;58(7):681686.Google Scholar
3. Pollack, MH. Use of atypical antipsychotics for refractory anxiety. Curbside Consultant. 2002;1:12.Google Scholar
4. Keck, PE Jr, McElroy, SL, Friedman, LM. Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Psychopharmacol. 1992;12(Suppl 1):36S41S.Google Scholar
5. Simon, NM, Worthington, JJ, Doyle, AC. Levetiracetam for the treatment of social anxiety disorder. Poster presented at: Annual Meeting of the Anxiety Disorders Association of America; March 13, 2004; Miami, FL.Google Scholar
6. Barlow, DH, Gorman, JM, Shear, MK, Woods, SW. Cognitive-behavioral therapy, imipramine, or their combinations for panic disorder: A randomized controlled trial. JAMA. 2000;283(19):25292536.Google Scholar
7. Pollack, MH. Panic disorder: the course and outcome of treatment. In: Rosenbaum, JF, Pollack, MH, eds. Panic Disorder and Its Treatment. New York, NY: Marcel Dekker; 1998.CrossRefGoogle Scholar
8. Brown, TA, Barlow, DH. Long-term outcome in cognitive-behavioral treatment for panic disorder: clinical predictors and alternative strategies for assessment. J Consult Clin Psychol. 1995;63(5):754765.Google Scholar
9. Liebowitz, MR, Heimberg, RG, Schneier, FR, et al. Cognitive-behavioral group therapy versus phenelzine in social phobia:?long-term outcome. Depress Anxiety. 1999;10(3):8998.3.0.CO;2-5>CrossRefGoogle ScholarPubMed
10. Feltner, DE, Crockatt, JG, Dubovsky, SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23(3):240249.CrossRefGoogle ScholarPubMed